MarketPulse

hypertrophic cardiomyopathy

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cytokinetics Q1 2026 Results Due May 5; MYQORZO® Updates Expected

Cytokinetics will report Q1 2026 earnings May 5, discussing MYQORZO® commercialization and pipeline progress in heart failure treatments.
CYTKearnings reportheart failure
The Motley FoolThe Motley Fool··Eric Volkman

JPMorgan Lifts Edgewise Therapeutics on Pipeline Optimism, Stock Surges

JPMorgan raises Edgewise Therapeutics price target to $45, citing positive long-term clinical data for EDG-7500 and sevasemten. Stock rises 2.18%.
AMJBJPMJPMpCJPMpDJPMpJ+5clinical databiotech
BenzingaBenzinga··Gav Blaxberg

Edgewise Therapeutics' $3.1B Bet on Two Blockbuster Drug Candidates

Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.
BMYCELGrALNYEWTXFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Cytokinetics, Incorporated

Cytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials